Amarin Corp Plc (AMRN)

[ziploc_1]

At the Goldman C.C., Berg, when asked about an FDC, mentioned that Amarin was "waiting for feedback from regulatory bodies".
This comment from Berg made me speculate about the following...

1. Amarin has already discussed an FDC with the FDA
2. The FDA has previously made the point, during the 2019 Adcom, that Vascepa can(or even should) be used in conjunction with a statin...so I see no reason why the FDA would balk at approving an FDC.
3. The main reason for Amarin holding back on a FDC now would be the cost to manufacture and market it.
4. The cost to consumers for an FDC could be little changed from the cost of Vascepa.
5. An FDC would not lower the market for Vascepa, but instead, it would advertise the notion to patients and Docs that Vascepa (or an FDC with Vascepa plus a statin) is effective for reducing CVD....and, as a result, stimulate the use of both